SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Predictive Oncology Inc. POAI NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Predictive Oncology Inc. (POAI) is a Medical - Instruments & Supplies company in the Healthcare sector, currently trading at $3.50. It has a SharesGrow Score of 28/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: POAI trades at a trailing Price-to-Earnings (P/E) of -0.4 (S&P 500 average ~25).

Financials: revenue is $125,284, -27.6%/yr average growth. Net income is $233M (loss), growing at -578.8%/yr. Net profit margin is -186053.4% (negative). Gross margin is 42% (-24.4 pp trend).

Balance sheet: total debt is $2M against $48M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 10.02 (strong liquidity). Debt-to-assets is 2.9%. Total assets: $53M.

Analyst outlook: 0 / 1 analysts rate POAI as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 20/100 (Fail), Income 10/100 (Fail).

POAI SharesGrow Score Overview

35/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — POAI

No analyst coverage available for this stock.

POAI: -27.6%/yr revenue is, -578.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet POAI: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 10.02 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

POAI: Gross margin is 42% (-24.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 1 analysts rate POAI as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

POAI: Net profit margin is -186053.4%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range1.21-45.9

Volume212.41K

Avg Volume (30D)141.65K

Market Cap$2.54M

Beta (1Y)1.35

Share Statistics

EPS (TTM)-13.37

Shares Outstanding$17.43M

IPO Date2010-05-03

Employees23

CEORaymond F. Vennare

Financial Highlights & Ratios

Revenue (TTM)$125.28K

Gross Profit$52.66K

EBITDA$-232.85M

Net Income$-233.1M

Operating Income$-232.85M

Total Cash$10.79M

Total Debt$1.56M

Net Debt$-9.23M

Total Assets$52.89M

Price / Earnings (P/E)-0.3

Price / Sales (P/S)20.28

Analyst Forecast

Rating ConsensusHold

Analysts Covering1

Buy 0% Hold 100% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS74039M4087

Price Chart

POAI

Predictive Oncology Inc. ↗ · NASDAQ Capital Marke

Healthcare • Medical - Instruments & Supplies

1.21 52WK RANGE 45.90

People Also View

Intuitive Surgical, Inc.

Stereotaxis, Inc.

Microbot Medical Inc.

Daxor Corporation

Sharps Technology, Inc.

Milestone Scientific Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message